<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78926">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906346</url>
  </required_header>
  <id_info>
    <org_study_id>R01-DA033364-01</org_study_id>
    <nct_id>NCT01906346</nct_id>
  </id_info>
  <brief_title>Impact of a Non-Drug Choice on Cocaine Reinforcement</brief_title>
  <official_title>Impact of a Non-Drug Choice on Cocaine Reinforcement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine-use disorders continue to be a significant public health concern, yet no effective
      medications have been identified. The goal of this study is to establish a research platform
      for the development of medications for treatment of cocaine abuse and dependence. This study
      will incorporate self-administration procedures and a non-drug alternative reinforcer, which
      is hypothesized to reduce the reinforcing effects of cocaine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of injections of self-administered cocaine</measure>
    <time_frame>per 6-hr daily session, 13 total sessions</time_frame>
    <safety_issue>No</safety_issue>
    <description>The reinforcing effects of cocaine will be assessed when an alternative reinforcer of varying values is available as an alternative using a modified progressive-ratio procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Subjective Effects Questionnaire</measure>
    <time_frame>per 6-hr daily session, 13 total sessions</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will complete a subjective effects questionnaire that will include items relating to drug effects and general mood and rated on a 100-unit Visual Analog Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Effects</measure>
    <time_frame>per 6-hr daily session, 13 total sessions</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Physiological measures include heart rate and blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects Questionnaire</measure>
    <time_frame>per 6-hr daily session, 13 total sessions</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Side Effects questions will query subjects about common effects of centrally active medications.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Low Value Alternative Reinforcer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low value reinforcer will be made available as an alternative to cocaine and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Value Reinforcer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A medium value reinforcer will be made available as an alternative to cocaine and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Value Reinforcer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high value reinforcer will be made available as an alternative to cocaine and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine</intervention_name>
    <description>Three active doses of cocaine will be made available for self-administration during experimental sessions.</description>
    <arm_group_label>Low Value Alternative Reinforcer</arm_group_label>
    <arm_group_label>Medium Value Reinforcer</arm_group_label>
    <arm_group_label>High Value Reinforcer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cocaine will be made available for self-administration during experimental sessions.</description>
    <arm_group_label>Low Value Alternative Reinforcer</arm_group_label>
    <arm_group_label>Medium Value Reinforcer</arm_group_label>
    <arm_group_label>High Value Reinforcer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cocaine dependence, otherwise healthy

        Exclusion Criteria:

          -  Laboratory results outside of clinically acceptable ranges, history of or current
             serious physical or psychiatric disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua A Lile, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William W Stoops, Ph.D.</last_name>
    <phone>859-257-5388</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratory of Human Behavioral Pharmacology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frances Wagner, RN</last_name>
      <phone>859-257-5388</phone>
    </contact>
    <investigator>
      <last_name>Joshua Lile, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joshua A. Lile, Ph.D.</investigator_full_name>
    <investigator_title>Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
